histamine has been researched along with Malignant Melanoma in 52 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The safety and efficacy of immunotherapy with histamine dihydrochloride (HDC), interleukin-2 (IL-2) and interferon-alpha2b (IFN) compared with dacarbazine (DTIC) in adult patients with stage IV melanoma was evaluated." | 9.12 | Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma. ( Anderson, R; Burdette-Radoux, S; Gehlsen, K; Hauschild, A; Hellstrand, K; Middleton, M; Naredi, P; Thomson, D, 2007) |
| "A phase III, multicenter, randomized, parallel group study comparing IL-2 plus histamine with IL-2 alone was conducted in 305 patients with advanced metastatic melanoma." | 9.10 | Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. ( Agarwala, SS; Belt, R; Feun, L; Gehlsen, KR; Glaspy, J; Gonzalez, R; Gutheil, J; Hellstrand, K; Hersh, E; Kirkwood, JM; Meyskens, F; Mitchell, M; Naredi, P; O'Day, SJ; Whitman, E; Wood, D, 2002) |
| "The aim of this study was to compare the quality-of-life (QOL) effects of interleukin-2 (IL-2) alone with those of IL-2 plus histamine dihydrochloride in the setting of a multicenter, randomized trial for patients with metastatic melanoma." | 9.10 | The health-related quality-of-life impact of histamine dihydrochloride plus interleukin-2 compared with interleukin-2 alone in patients with metastatic melanoma. ( Ackerman, SJ; Agarwala, SS; Beusterien, KM; Gehlsen, K; Glaspy, J; Naredi, P; Plante, K; Wood, D, 2003) |
| "Interleukin-6 is an autocrine growth factor in advanced stage melanoma and biosynthesis of IL-6 is increased by histamine in various cell lines." | 8.80 | Biosynthesis of interleukin-6, an autocrine growth factor for melanoma, is regulated by melanoma-derived histamine. ( Darvas, Z; Falus, A; Hegyesi, H; László, V; Molnár, EL; Szalai, C; Tóth, S, 2000) |
| "The aims of the work were to improve our knowledge of the role of H4R in melanoma proliferation and assess in vivo the therapeutic efficacy of histamine, clozapine and JNJ28610244, an H4R agonist, in a preclinical metastatic model of melanoma." | 7.85 | Histamine therapeutic efficacy in metastatic melanoma: Role of histamine H4 receptor agonists and opportunity for combination with radiation. ( Blanco, H; Cricco, GP; Herrero Ducloux, MV; Martinel Lamas, DJ; Massari, NA; Medina, VA; Nicoud, MB; Rivera, ES; Sambuco, L, 2017) |
| "This study was conducted to determine if differences in histidine decarboxylase expression and histamine levels exist between B16F10 melanoma cells and non-cancerous Melan-A melanocytes." | 7.77 | Up-regulation of histidine decarboxylase expression and histamine content in B16F10 murine melanoma cells. ( Clark, S; Davis, SC; Green, TL; Gruetter, CA; Hayes, JR, 2011) |
| "We have previously reported that histamine at micromolar concentrations reduces the proliferation of melanoma cell lines." | 7.77 | Role of H4 receptor in histamine-mediated responses in human melanoma. ( Bergoc, RM; Cricco, GP; Croci, M; Martinel Lamas, DJ; Massari, NA; Medina, VA; Rivera, ES; Sambuco, L, 2011) |
| "Histamine is a recognized growth factor in melanoma, and exogenous histamine produces a dual effect on proliferation." | 7.75 | Involvement of hydrogen peroxide in histamine-induced modulation of WM35 human malignant melanoma cell proliferation. ( Bergoc, RM; Cricco, GP; Martín, GA; Massari, NA; Medina, VA; Rivera, ES, 2009) |
| "IL-6 inhibited the proliferation of WM35 melanoma cells and increased significantly the expression of histidine decarboxylase as well as histamine production." | 7.71 | Inhibition of human primary melanoma cell proliferation by histamine is enhanced by interleukin-6. ( Bergoc, R; Cricco, G; Darvas, Z; Falus, A; Fitzsimons, C; Hegyesi, H; Kovács, P; Lázár-Molnár, E; Martin, G; Pállinger, E; Rivera, ES; Tóth, S, 2002) |
| "We have demonstrated previously that cisplatin (DDP) and tamoxifen (TAM) act synergistically to kill human melanoma T-289 cells, and that the observed synergy is lost in the 3-fold TAM-resistant subline, 289/TAM6." | 7.69 | Synergy between tamoxifen and cisplatin in human melanoma cells is dependent on the presence of antiestrogen-binding sites. ( Albright, KD; Christen, RD; Howell, SB; Jones, JA; McClay, EF, 1997) |
| "Histamine induced a concentration-dependent increase in intracellular cyclic-AMP of the two human melanoma cell lines SK23 and DX3." | 7.67 | Demonstration of histamine H2 receptors on human melanoma cells. ( Evanson, JM; Hart, IR; Taylor, DJ; Whitehead, RJ; Woolley, DE, 1988) |
| "Melanoma patients having liver metastases were treated with IL-2 with or without HDC within a randomized, multicenter, phase III trial." | 6.71 | Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104). ( Asemissen, AM; Gehlsen, K; Hellstrand, K; Keilholz, U; Letsch, A; Scheibenbogen, C; Schmittel, A; Thiel, E; Thorén, F, 2005) |
| " All reported adverse events were included in the analysis." | 6.71 | Treatment with histamine dihydrochloride and interleukin-2 in patients with advanced metastatic malignant melanoma: a detailed safety analysis. ( Agarwala, SS; Gehlsen, KR; Glaspy, J; Kass, CL; Naredi, P; O'Day, SJ, 2003) |
| "Histamine 1 mg s." | 6.70 | A phase II study of outpatient subcutaneous histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma. ( Bastholt, L; Fode, K; Larsen, S; Rytter, C; Schmidt, H; Von Der Maase, H, 2002) |
| "Histamine has the potential to optimize cytokine-induced activation of T cells and natural killer cells; therefore, the addition of histamine to cytokine treatment may improve treatment efficacy." | 6.44 | Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma. ( Ho, AD; Perz, JB, 2008) |
| "Two histamine-treated patients showed complete resolution of extensive liver metastasis." | 5.29 | Histamine in immunotherapy of advanced melanoma: a pilot study. ( Asztély, M; Hafström, L; Hellstrand, K; Hermodsson, S; Lindner, P; Lundholm, K; Naredi, P; Rudenstam, CM, 1994) |
| "Histamine is an established growth factor for gastric and colorectal cancer." | 5.29 | In vitro effect of histamine and histamine H1 and H2 receptor antagonists on cellular proliferation of human malignant melanoma cell lines. ( Akhter, J; Morris, DL; Reynolds, JL, 1996) |
| "Histamine was found to be a potent activator of phospholipase C, leading to polyphosphoinositide hydrolysis and subsequent intracellular Ca2+ mobilization." | 5.28 | Histamine as a growth factor and chemoattractant for human carcinoma and melanoma cells: action through Ca2(+)-mobilizing H1 receptors. ( de Laat, SW; Ladoux, A; Moolenaar, WH; Remorie, R; Tertoolen, LG; Tilly, BC; Verlaan, I, 1990) |
| "Histamine treatment accelerated tumor growth, but only in normal animals and had little effect on tumor growth in immunocompromised hosts." | 5.27 | The effect of histamine, antihistamines, and a mast cell stabilizer on the growth of cloudman melanoma cells in DBA/2 mice. ( Askenase, PW; Nordlund, JJ, 1983) |
| "The safety and efficacy of immunotherapy with histamine dihydrochloride (HDC), interleukin-2 (IL-2) and interferon-alpha2b (IFN) compared with dacarbazine (DTIC) in adult patients with stage IV melanoma was evaluated." | 5.12 | Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma. ( Anderson, R; Burdette-Radoux, S; Gehlsen, K; Hauschild, A; Hellstrand, K; Middleton, M; Naredi, P; Thomson, D, 2007) |
| "The aim of this study was to compare the quality-of-life (QOL) effects of interleukin-2 (IL-2) alone with those of IL-2 plus histamine dihydrochloride in the setting of a multicenter, randomized trial for patients with metastatic melanoma." | 5.10 | The health-related quality-of-life impact of histamine dihydrochloride plus interleukin-2 compared with interleukin-2 alone in patients with metastatic melanoma. ( Ackerman, SJ; Agarwala, SS; Beusterien, KM; Gehlsen, K; Glaspy, J; Naredi, P; Plante, K; Wood, D, 2003) |
| "A phase III, multicenter, randomized, parallel group study comparing IL-2 plus histamine with IL-2 alone was conducted in 305 patients with advanced metastatic melanoma." | 5.10 | Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. ( Agarwala, SS; Belt, R; Feun, L; Gehlsen, KR; Glaspy, J; Gonzalez, R; Gutheil, J; Hellstrand, K; Hersh, E; Kirkwood, JM; Meyskens, F; Mitchell, M; Naredi, P; O'Day, SJ; Whitman, E; Wood, D, 2002) |
| "Recent clinical trials in melanoma and leukemia have demonstrated potential for increased survival time and improved remission when histamine dihydrochloride is added to cytokine monotherapy." | 5.10 | Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2. ( Agarwala, SS; Cosford, R; Danson, S; Gehlsen, K; Glaspy, J; Laurent, A; McMasters, K; Middleton, M; Naredi, P; O'Day, S; Sarno, M; Whitman, E, 2002) |
| "Interleukin-6 is an autocrine growth factor in advanced stage melanoma and biosynthesis of IL-6 is increased by histamine in various cell lines." | 4.80 | Biosynthesis of interleukin-6, an autocrine growth factor for melanoma, is regulated by melanoma-derived histamine. ( Darvas, Z; Falus, A; Hegyesi, H; László, V; Molnár, EL; Szalai, C; Tóth, S, 2000) |
| "The aims of the work were to improve our knowledge of the role of H4R in melanoma proliferation and assess in vivo the therapeutic efficacy of histamine, clozapine and JNJ28610244, an H4R agonist, in a preclinical metastatic model of melanoma." | 3.85 | Histamine therapeutic efficacy in metastatic melanoma: Role of histamine H4 receptor agonists and opportunity for combination with radiation. ( Blanco, H; Cricco, GP; Herrero Ducloux, MV; Martinel Lamas, DJ; Massari, NA; Medina, VA; Nicoud, MB; Rivera, ES; Sambuco, L, 2017) |
| "This study was conducted to determine if differences in histidine decarboxylase expression and histamine levels exist between B16F10 melanoma cells and non-cancerous Melan-A melanocytes." | 3.77 | Up-regulation of histidine decarboxylase expression and histamine content in B16F10 murine melanoma cells. ( Clark, S; Davis, SC; Green, TL; Gruetter, CA; Hayes, JR, 2011) |
| "We have previously reported that histamine at micromolar concentrations reduces the proliferation of melanoma cell lines." | 3.77 | Role of H4 receptor in histamine-mediated responses in human melanoma. ( Bergoc, RM; Cricco, GP; Croci, M; Martinel Lamas, DJ; Massari, NA; Medina, VA; Rivera, ES; Sambuco, L, 2011) |
| " Addressing this problem, different melanoma and squamous cell carcinoma cell lines were co-cultivated with primary, dermal MC for 24 h and gene or protein expression of cytokines tumor necrosis factor (TNF-α), interleukin-6 (IL-6) and interleukin-8 (IL-8) estimated." | 3.77 | Mast cell-derived TNF-α and histamine modify IL-6 and IL-8 expression and release from cutaneous tumor cells. ( Artuc, M; Babina, M; Guhl, S; Steckelings, UM; Unger, T; Zuberbier, T, 2011) |
| "There have been many proposed theories for effectively treating melanoma, especially through the regulation of histamine." | 3.73 | Site specific therapy: an integrative approach to treating melanoma. ( Kavekos, M, 2005) |
| "IL-6 inhibited the proliferation of WM35 melanoma cells and increased significantly the expression of histidine decarboxylase as well as histamine production." | 3.71 | Inhibition of human primary melanoma cell proliferation by histamine is enhanced by interleukin-6. ( Bergoc, R; Cricco, G; Darvas, Z; Falus, A; Fitzsimons, C; Hegyesi, H; Kovács, P; Lázár-Molnár, E; Martin, G; Pállinger, E; Rivera, ES; Tóth, S, 2002) |
| "Histamine displayed specific and saturable binding to membrane fractions of the human melanoma cell line MM96E (Kd = 72." | 3.69 | Dimaprit analogues inhibit tyrosinase via a disulphide breakdown product independently of the histamine H2 receptor. ( Fechner, GA; Jacobs, JJ; Parsons, PG, 1994) |
| "We have demonstrated previously that cisplatin (DDP) and tamoxifen (TAM) act synergistically to kill human melanoma T-289 cells, and that the observed synergy is lost in the 3-fold TAM-resistant subline, 289/TAM6." | 3.69 | Synergy between tamoxifen and cisplatin in human melanoma cells is dependent on the presence of antiestrogen-binding sites. ( Albright, KD; Christen, RD; Howell, SB; Jones, JA; McClay, EF, 1997) |
| "Histamine induced a concentration-dependent increase in intracellular cyclic-AMP of the two human melanoma cell lines SK23 and DX3." | 3.67 | Demonstration of histamine H2 receptors on human melanoma cells. ( Evanson, JM; Hart, IR; Taylor, DJ; Whitehead, RJ; Woolley, DE, 1988) |
| " Mice: While feeding mice a pyridoxal phosphate-free diet, a Harding-Passey melanoma was inoculated: The tumour weights were slightly lower in the case of animals put on the diet than in controls." | 3.66 | [The effect of experimentally induced histamine deficiency on growth and rate of taking of model tumours (author's transl)]. ( Fischer, G; Möse, JR; Moser, M, 1980) |
| " All reported adverse events were included in the analysis." | 2.71 | Treatment with histamine dihydrochloride and interleukin-2 in patients with advanced metastatic malignant melanoma: a detailed safety analysis. ( Agarwala, SS; Gehlsen, KR; Glaspy, J; Kass, CL; Naredi, P; O'Day, SJ, 2003) |
| "Melanoma patients having liver metastases were treated with IL-2 with or without HDC within a randomized, multicenter, phase III trial." | 2.71 | Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104). ( Asemissen, AM; Gehlsen, K; Hellstrand, K; Keilholz, U; Letsch, A; Scheibenbogen, C; Schmittel, A; Thiel, E; Thorén, F, 2005) |
| "Histamine 1 mg s." | 2.70 | A phase II study of outpatient subcutaneous histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma. ( Bastholt, L; Fode, K; Larsen, S; Rytter, C; Schmidt, H; Von Der Maase, H, 2002) |
| "Histamine has been demonstrated to be involved in cell proliferation, embryonic development, and tumour growth." | 2.46 | Histamine and histamine receptor antagonists in cancer biology. ( Alonso-Tejerina, E; Asumendi, A; Blaya, B; Boyano, MD; Burgos-Bretones, J; Jangi, SM; Nicolau-Galmés, F; Ortega-Martínez, I; Pérez-Yarza, G, 2010) |
| "Histamine has the potential to optimize cytokine-induced activation of T cells and natural killer cells; therefore, the addition of histamine to cytokine treatment may improve treatment efficacy." | 2.44 | Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma. ( Ho, AD; Perz, JB, 2008) |
| "Two histamine-treated patients showed complete resolution of extensive liver metastasis." | 1.29 | Histamine in immunotherapy of advanced melanoma: a pilot study. ( Asztély, M; Hafström, L; Hellstrand, K; Hermodsson, S; Lindner, P; Lundholm, K; Naredi, P; Rudenstam, CM, 1994) |
| "Histamine was found to be a potent activator of phospholipase C, leading to polyphosphoinositide hydrolysis and subsequent intracellular Ca2+ mobilization." | 1.28 | Histamine as a growth factor and chemoattractant for human carcinoma and melanoma cells: action through Ca2(+)-mobilizing H1 receptors. ( de Laat, SW; Ladoux, A; Moolenaar, WH; Remorie, R; Tertoolen, LG; Tilly, BC; Verlaan, I, 1990) |
| "Histamine treatment accelerated tumor growth, but only in normal animals and had little effect on tumor growth in immunocompromised hosts." | 1.27 | The effect of histamine, antihistamines, and a mast cell stabilizer on the growth of cloudman melanoma cells in DBA/2 mice. ( Askenase, PW; Nordlund, JJ, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (19.23) | 18.7374 |
| 1990's | 7 (13.46) | 18.2507 |
| 2000's | 27 (51.92) | 29.6817 |
| 2010's | 6 (11.54) | 24.3611 |
| 2020's | 2 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J | 1 |
| Peng, G | 1 |
| Zhu, K | 1 |
| Jie, X | 1 |
| Xu, Y | 2 |
| Rao, X | 1 |
| Chen, Y | 1 |
| Xing, B | 1 |
| Wu, G | 1 |
| Shi, L | 1 |
| Kim, HY | 1 |
| Jung, H | 1 |
| Kim, HM | 2 |
| Jeong, HJ | 2 |
| Massari, NA | 3 |
| Nicoud, MB | 1 |
| Sambuco, L | 2 |
| Cricco, GP | 3 |
| Martinel Lamas, DJ | 2 |
| Herrero Ducloux, MV | 1 |
| Blanco, H | 1 |
| Rivera, ES | 4 |
| Medina, VA | 3 |
| Martín, GA | 1 |
| Bergoc, RM | 2 |
| Blaya, B | 1 |
| Nicolau-Galmés, F | 1 |
| Jangi, SM | 2 |
| Ortega-Martínez, I | 1 |
| Alonso-Tejerina, E | 1 |
| Burgos-Bretones, J | 1 |
| Pérez-Yarza, G | 2 |
| Asumendi, A | 2 |
| Boyano, MD | 2 |
| Davis, SC | 1 |
| Clark, S | 1 |
| Hayes, JR | 1 |
| Green, TL | 1 |
| Gruetter, CA | 1 |
| Croci, M | 1 |
| Artuc, M | 1 |
| Guhl, S | 1 |
| Babina, M | 1 |
| Unger, T | 1 |
| Steckelings, UM | 1 |
| Zuberbier, T | 1 |
| Oh, HA | 2 |
| Nam, SY | 1 |
| Han, NR | 1 |
| Kim, YS | 1 |
| Kim, JH | 1 |
| Lee, SJ | 1 |
| Kim, MH | 1 |
| Moon, PD | 1 |
| Agarwala, SS | 8 |
| Hellstrand, K | 8 |
| Naredi, P | 10 |
| Lázár-Molnár, E | 1 |
| Hegyesi, H | 8 |
| Pállinger, E | 3 |
| Kovács, P | 1 |
| Tóth, S | 2 |
| Fitzsimons, C | 2 |
| Cricco, G | 2 |
| Martin, G | 2 |
| Bergoc, R | 2 |
| Darvas, Z | 7 |
| Falus, A | 8 |
| Schmidt, H | 1 |
| Larsen, S | 1 |
| Bastholt, L | 1 |
| Fode, K | 1 |
| Rytter, C | 1 |
| Von Der Maase, H | 1 |
| Kanda, N | 1 |
| Watanabe, S | 1 |
| Beusterien, KM | 1 |
| Ackerman, SJ | 1 |
| Plante, K | 1 |
| Glaspy, J | 4 |
| Wood, D | 2 |
| Gehlsen, K | 5 |
| Sakurai, E | 2 |
| Schwelberger, HG | 1 |
| Rivera, E | 2 |
| Othsu, H | 1 |
| Watanabe, T | 2 |
| O'Day, SJ | 2 |
| Kass, CL | 1 |
| Gehlsen, KR | 2 |
| ULTMANN, JE | 1 |
| MUTTER, RD | 1 |
| TANNENBAUM, M | 1 |
| WARNER, RR | 1 |
| Asemissen, AM | 1 |
| Scheibenbogen, C | 1 |
| Letsch, A | 1 |
| Thorén, F | 1 |
| Schmittel, A | 1 |
| Thiel, E | 1 |
| Keilholz, U | 1 |
| Kavekos, M | 1 |
| Horváth, B | 2 |
| Pós, Z | 1 |
| Molnár, V | 1 |
| Díaz-Pérez, JL | 1 |
| Ochoa-Lizarralde, B | 1 |
| Martín-Ruiz, I | 1 |
| Gardeazabal, J | 1 |
| Díaz-Ramón, JL | 1 |
| Middleton, M | 2 |
| Hauschild, A | 1 |
| Thomson, D | 1 |
| Anderson, R | 1 |
| Burdette-Radoux, S | 1 |
| Perz, JB | 1 |
| Ho, AD | 1 |
| Desser, H | 1 |
| Niebauer, GW | 1 |
| Gebhart, W | 1 |
| Nordlund, JJ | 1 |
| Askenase, PW | 1 |
| Möse, JR | 1 |
| Moser, M | 1 |
| Fischer, G | 1 |
| Lindner, P | 1 |
| Lundholm, K | 1 |
| Rudenstam, CM | 1 |
| Hermodsson, S | 2 |
| Asztély, M | 1 |
| Hafström, L | 1 |
| Fechner, GA | 1 |
| Jacobs, JJ | 1 |
| Parsons, PG | 1 |
| Reynolds, JL | 1 |
| Akhter, J | 1 |
| Morris, DL | 1 |
| László, V | 2 |
| Radvány, Z | 2 |
| Kiss, B | 1 |
| Bencsáth, M | 1 |
| Jones, JA | 1 |
| Albright, KD | 1 |
| Christen, RD | 1 |
| Howell, SB | 1 |
| McClay, EF | 1 |
| Mellqvist, UH | 1 |
| Brune, M | 1 |
| Heninger, E | 1 |
| Lázár, E | 1 |
| Szalai, C | 2 |
| Otsu, H | 1 |
| Molnár, EL | 2 |
| Mitchell, M | 1 |
| Gutheil, J | 1 |
| Whitman, E | 2 |
| Gonzalez, R | 1 |
| Hersh, E | 1 |
| Feun, L | 1 |
| Belt, R | 1 |
| Meyskens, F | 1 |
| Kirkwood, JM | 1 |
| Schadendorf, D | 1 |
| Urba, WJ | 1 |
| Alvord, WG | 1 |
| Sarno, M | 1 |
| Laurent, A | 1 |
| McMasters, K | 1 |
| O'Day, S | 1 |
| Danson, S | 1 |
| Cosford, R | 1 |
| Tilly, BC | 1 |
| Tertoolen, LG | 1 |
| Remorie, R | 1 |
| Ladoux, A | 1 |
| Verlaan, I | 1 |
| de Laat, SW | 1 |
| Moolenaar, WH | 1 |
| Bernd, A | 1 |
| Altmeyer, P | 1 |
| Schäfer, G | 1 |
| Marsch, WC | 1 |
| Holzmann, H | 1 |
| Whitehead, RJ | 1 |
| Taylor, DJ | 1 |
| Evanson, JM | 1 |
| Hart, IR | 1 |
| Woolley, DE | 1 |
| Kölmel, KF | 1 |
| Lochmanová, A | 1 |
| Borysová, L | 1 |
| Lochman, I | 1 |
| Håkanson, R | 1 |
6 reviews available for histamine and Malignant Melanoma
| Article | Year |
|---|---|
Histamine and histamine receptor antagonists in cancer biology.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Histamine; Histamine Antagonists; Histamin | 2010 |
Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Antioxidants; Carcinoma, Renal Cell; Dose-Response Relationship, Dru | 2008 |
Histamine and cytokine therapy.
Topics: Animals; Antineoplastic Agents; Cimetidine; Combined Modality Therapy; Histamine; Humans; Immunother | 1998 |
Biosynthesis of interleukin-6, an autocrine growth factor for melanoma, is regulated by melanoma-derived histamine.
Topics: Glucose-6-Phosphate Isomerase; Growth Substances; Histamine; Humans; Interleukin-6; Melanoma; RNA, M | 2000 |
Histamine as an adjunct to immunotherapy.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Apoptosis; Cytotoxicity, Immunologic; Histam | 2002 |
Histamine in cancer immunotherapy: a preclinical background.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Cytotoxicity, Immunologic; Histamine; Humans | 2002 |
7 trials available for histamine and Malignant Melanoma
| Article | Year |
|---|---|
A phase II study of outpatient subcutaneous histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma.
Topics: Adult; Aged; Ambulatory Care; Chi-Square Distribution; Dose-Response Relationship, Drug; Drug Admini | 2002 |
The health-related quality-of-life impact of histamine dihydrochloride plus interleukin-2 compared with interleukin-2 alone in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Femal | 2003 |
Treatment with histamine dihydrochloride and interleukin-2 in patients with advanced metastatic malignant melanoma: a detailed safety analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Chills; Female; F | 2003 |
Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104).
Topics: CD3 Complex; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cytokines; Flow Cytometry; Hist | 2005 |
Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Histamine; Humans; | 2007 |
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Consumer Product Saf | 2002 |
Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Interactions | 2002 |
39 other studies available for histamine and Malignant Melanoma
| Article | Year |
|---|---|
PD-1
Topics: Animals; Cromolyn Sodium; Cytokines; Histamine; Immunotherapy; Mast Cells; Melanoma; Mice; Phosphati | 2023 |
Surfactin exerts an anti-cancer effect through inducing allergic reactions in melanoma skin cancer.
Topics: Amino Acid Sequence; Animals; Anti-Allergic Agents; Antineoplastic Agents; Apoptosis; Cell Degranula | 2021 |
Histamine therapeutic efficacy in metastatic melanoma: Role of histamine H4 receptor agonists and opportunity for combination with radiation.
Topics: Animals; Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Cell Proliferation; Cellular Senescenc | 2017 |
Involvement of hydrogen peroxide in histamine-induced modulation of WM35 human malignant melanoma cell proliferation.
Topics: Catalase; Cell Proliferation; Cellular Senescence; Enzyme Activation; Histamine; Humans; Hydrogen Pe | 2009 |
Up-regulation of histidine decarboxylase expression and histamine content in B16F10 murine melanoma cells.
Topics: Animals; Cells, Cultured; Histamine; Histidine Decarboxylase; Melanocytes; Melanoma; Mice; Up-Regula | 2011 |
Role of H4 receptor in histamine-mediated responses in human melanoma.
Topics: Cell Differentiation; Cell Growth Processes; Cell Line, Tumor; Guanidines; Histamine; Humans; Imidaz | 2011 |
Mast cell-derived TNF-α and histamine modify IL-6 and IL-8 expression and release from cutaneous tumor cells.
Topics: Antibodies; Carcinoma, Squamous Cell; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Cultu | 2011 |
The critical role of mast cell-derived hypoxia-inducible factor-1α in human and mice melanoma growth.
Topics: Animals; Apoptosis; Blotting, Western; Bone Marrow; Cell Hypoxia; Cell Proliferation; Cytokines; End | 2013 |
Interleukin-2 and histamine dihydrochloride in metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Histamine; Humans; Interleukin-2; Melanoma; Neoplasm | 2002 |
Inhibition of human primary melanoma cell proliferation by histamine is enhanced by interleukin-6.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Bucladesine; Cell Division; Colforsin; Cyclic AMP-Dependent | 2002 |
Histamine inhibits the production of interferon-induced protein of 10 kDa in human squamous cell carcinoma and melanoma.
Topics: Carcinoma, Squamous Cell; Chemokine CXCL10; Chemokines, CXC; Cyclic AMP; Cyclic AMP-Dependent Protei | 2002 |
Autonomous histamine metabolism in human melanoma cells.
Topics: Amine Oxidase (Copper-Containing); Cell Division; Histamine; Histamine N-Methyltransferase; Histidin | 2003 |
CLINICAL, CYTOLOGIC, AND BIOCHEMICAL STUDIES IN SYSTEMIC MAST CELL DISEASE.
Topics: Anemia; Electrons; Glycosaminoglycans; Histamine; Humans; Leukopenia; Mast Cells; Mastocytosis, Syst | 1964 |
Immunotherapy with histamine and interleukin 2 in malignant melanoma with liver metastasis.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Histamine; Immunotherapy; Interleukin-2; Liver | 2004 |
Site specific therapy: an integrative approach to treating melanoma.
Topics: Antineoplastic Agents; Cryotherapy; Histamine; Histamine H1 Antagonists; Histamine H2 Antagonists; H | 2005 |
Histamine elevates the expression of Ets-1, a protooncogen in human melanoma cell lines through H2 receptor.
Topics: Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Histamine; Humans; Melanoma; Proto-Oncogen | 2005 |
H1 histamine receptor antagonists induce genotoxic and caspase-2-dependent apoptosis in human melanoma cells.
Topics: Apoptosis; Caspase 2; Caspases; Cell Line, Tumor; Cytosol; DNA Damage; Enzyme Activation; Fibroblast | 2006 |
Combination of cimetidine with other drugs for treatment of cancer.
Topics: Aged; Animals; Cimetidine; Coumarins; Female; Guanidines; Histamine; Humans; Interferons; Male; Mela | 1983 |
[Polyamine and histamine contents in the blood of pigmented, depigmented and melanoma bearing Lipizzaner horses].
Topics: Aging; Animals; Hair Color; Histamine; Horse Diseases; Horses; Melanoma; Polyamines; Skin Neoplasms; | 1980 |
The effect of histamine, antihistamines, and a mast cell stabilizer on the growth of cloudman melanoma cells in DBA/2 mice.
Topics: Animals; Chromones; Cimetidine; Histamine; Histamine Antagonists; Immunosuppression Therapy; Male; M | 1983 |
[The effect of experimentally induced histamine deficiency on growth and rate of taking of model tumours (author's transl)].
Topics: Animals; Carcinoma 256, Walker; Clostridium; Diet; Histamine; Melanoma; Mice; Neoplasms, Experimenta | 1980 |
Histamine in immunotherapy of advanced melanoma: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Histamine; Humans; Interferon-a | 1994 |
Dimaprit analogues inhibit tyrosinase via a disulphide breakdown product independently of the histamine H2 receptor.
Topics: Biotransformation; Cell Line; Dimaprit; Disulfides; Histamine; Humans; Kinetics; Melanoma; Monopheno | 1994 |
In vitro effect of histamine and histamine H1 and H2 receptor antagonists on cellular proliferation of human malignant melanoma cell lines.
Topics: Cell Division; Cyclic AMP; Drug Interactions; Histamine; Histamine H1 Antagonists; Histamine H2 Anta | 1996 |
Histidine decarboxylase and intracellular histamine in melanoma cells and in a T cell line.
Topics: Cell Line; Enzyme Inhibitors; Histamine; Histamine Antagonists; Histidine Decarboxylase; Humans; Mel | 1997 |
Synergy between tamoxifen and cisplatin in human melanoma cells is dependent on the presence of antiestrogen-binding sites.
Topics: Binding, Competitive; Cisplatin; Histamine; Histamine Antagonists; Humans; Melanoma; Phenyl Ethers; | 1997 |
Reciprocal inhibitory interactions between interferon gamma and histamine in melanoma.
Topics: Enzyme Inhibitors; Gene Expression; Histamine; Histidine Decarboxylase; Humans; Interferon Type I; I | 2000 |
Turnover of histamine in human melanoma cell lines.
Topics: Histamine; Histamine Release; Histidine Decarboxylase; Humans; Melanoma; Tumor Cells, Cultured | 2000 |
Histamine as a potential autocrine regulator of melanoma.
Topics: Cell Division; Histamine; Humans; Melanoma; Tumor Cells, Cultured | 2001 |
Chemotherapy Foundation Symposium XVIII: Session on malignant melanoma.
Topics: Clinical Trials as Topic; Granulocyte-Macrophage Colony-Stimulating Factor; Histamine; Humans; Immun | 2001 |
The use of histamine in cancer immunotherapy.
Topics: Histamine; Humans; Immunotherapy; Melanoma | 2002 |
Are all hypotheses generated before data analysis prospective?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Consumer Produc | 2002 |
New applications of cancer immunotherapy.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Histamine; Humans; Immunolog | 2002 |
Histamine as a growth factor and chemoattractant for human carcinoma and melanoma cells: action through Ca2(+)-mobilizing H1 receptors.
Topics: Cell Division; Chemotaxis; DNA, Neoplasm; Epidermal Growth Factor; Growth Substances; HeLa Cells; Hi | 1990 |
Bleomycin enhances the tyrosinase activity of human malignant melanoma cells in culture.
Topics: Basidiomycota; Bleomycin; Catechol Oxidase; Cell Division; Cells, Cultured; Enzyme Activation; Hista | 1986 |
Demonstration of histamine H2 receptors on human melanoma cells.
Topics: Adenylyl Cyclases; Cimetidine; Cyclic AMP; Dose-Response Relationship, Drug; Histamine; Humans; Mela | 1988 |
[Decreased blood histamine levels in malignant melanoma].
Topics: Adult; Chromatography, High Pressure Liquid; Female; Histamine; Humans; Male; Melanoma; Middle Aged; | 1987 |
[The effect of histamine and theophylline and the formation of E rosettes].
Topics: Asthma; Histamine; Humans; Melanoma; Rhinitis, Allergic, Seasonal; Rosette Formation; Theophylline | 1986 |
Histidine decarboxylase in experimental tumours.
Topics: Animals; Carboxy-Lyases; Carcinoma 256, Walker; Cricetinae; Dopa Decarboxylase; Histamine; Melanoma; | 1966 |